Gennex Laboratories Ratios

Gennex Laboratories Ltd Ratios

The Gennex Laboratories Ltd Ratios page provides a complete fundamental analysis of Gennex Laboratories Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Gennex Laboratories Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Gennex Laboratories Ltd (NSE: , BSE: 531739) is currently trading at ₹9.40, with a market capitalization of ₹2.14B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Gennex Laboratories Ltd remains a key stock for fundamental analysis using Gennex Laboratories Ltd Ratios.

Gennex Laboratories Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Gennex Laboratories Ltd P/E ratio currently stands at 15.12, making it one of the most tracked metrics in Gennex Laboratories Ltd Ratios.

Historically, the Gennex Laboratories Ltd P/E ratio has shown strong fluctuations:

• 2024: 15.12
• 2023: 22.40
• 2022: 16.65
• 2021: 24.28
• 2020: 12.25

The decline in Gennex Laboratories Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Gennex Laboratories Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.47.

Historical P/B trend:

• 2024: 1.47
• 2023: 2.11
• 2022: 1.24
• 2021: 2.18

Gennex Laboratories Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Gennex Laboratories Ltd P/S ratio currently stands at 1.99, an important part of Gennex Laboratories Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 1.99
• 2023: 3.40
• 2022: 1.25
• 2021: 1.56

A stable or declining Gennex Laboratories Ltd P/S ratio indicates cautious market sentiment.

Gennex Laboratories Ltd Price to Cash Flow Ratio (P/CF)

The Gennex Laboratories Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Gennex Laboratories Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 0
• 2022: 3.28
• 2021: 19.61
• 2020: 0

The declining Gennex Laboratories Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Gennex Laboratories Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Gennex Laboratories Ltd EV currently stands at ₹2.54B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 2.54B
• 2023: 2.59B
• 2022: 741M
• 2021: 970.68M

Gennex Laboratories Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Gennex Laboratories Ltd EV/EBITDA ratio is currently 14.96, a key metric in Gennex Laboratories Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 14.96
• 2023: 14.91
• 2022: 15.66
• 2021: 17.72

Higher Gennex Laboratories Ltd EV/EBITDA suggests premium valuation.

Gennex Laboratories Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Gennex Laboratories Ltd D/E ratio is currently 0.15, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.15
• 2023: 0.11
• 2022: 0.01
• 2021: 0.23

Gennex Laboratories Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Gennex Laboratories Ltd ROE currently stands at 10.16%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 10.16
• 2023: 10.53
• 2022: 7.95
• 2021: 9.44

Gennex Laboratories Ltd maintains stable profitability levels.

Gennex Laboratories Ltd Ratios Analysis Summary

The Gennex Laboratories Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Gennex Laboratories Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Gennex Laboratories Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.